Clinical trial · Interventional
Procedures of Locoregional Analgesia and Quality of Life in Palliative Care Units
Procedures of Locoregional Analgesia and Quality of Life in Palliative Care
NCT01094912CI-TRIAL-00019003TALViSoPsuspendedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Number of patients in mobile palliative care units have pain of both nociceptive and neuropathic origin. In certain cases, procedures of locoregional analgesia can be helpful. The Purpose of this study is to evaluate the impact of techniques of locoregional analgesia in a palliative population
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| opioids | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Change in patients global quality of life
- timeFrame
- 1 week after first injection
- description
- To evaluate the change in patients global quality of life, assessed by the item 15 of the validated quality of life scale EORTC QLQ-C15 PAL. Evaluations will take place before the procedure of locoregional analgesia and 1 week after.
Secondary outcomes (1)
- measure
- change in patient's global quality of life
- timeFrame
- 2 days and 1 week after procedure
- description
- * evaluate the change in EORTC QLQ-C15 PAL score, assessed before the procedure of locoregional analgesia and 1 week after. * evaluate the change in patient's global quality of life, assessed by the item 15 of the validated quality of life scale EORTC QLQ-C15 PAL at 48 hours and 1 week post-procedure. * evaluate pain at 48 hours post-procedure * evaluate the change in doses of conventional treatments at 1 week
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient ≥ 18 years-old, male or female, whatever his/her ethnic group * Patient with untreatable cancer * Patient hospitalized in a palliative care unit, with a life expectancy ≥ 1 week * Pain unresponsive to conventional treatments * Effectiveness of the injection test * Signed informed consent Exclusion Criteria: * Patients \> 18 years-old * Patients with pain other than cancer pain * Patient's refusal * Coagulation disorders * Local infection * Known hypersensitivity to local analgesics * Inefficacy of the injection test. * Contraindication for analgesics
References
Publications (0)
Data not yet available
No reference posted for this study.